CU24555B1 - Combinación a dosis fija de paracetamol:amitriptilina - Google Patents
Combinación a dosis fija de paracetamol:amitriptilinaInfo
- Publication number
- CU24555B1 CU24555B1 CU2018000037A CU20180037A CU24555B1 CU 24555 B1 CU24555 B1 CU 24555B1 CU 2018000037 A CU2018000037 A CU 2018000037A CU 20180037 A CU20180037 A CU 20180037A CU 24555 B1 CU24555 B1 CU 24555B1
- Authority
- CU
- Cuba
- Prior art keywords
- paracetamol
- amitriptyline
- fixed
- dose combination
- synergy
- Prior art date
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title abstract 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000836 amitriptyline Drugs 0.000 title abstract 2
- 229960005489 paracetamol Drugs 0.000 title abstract 2
- 229940000425 combination drug Drugs 0.000 title 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>La presente invención describe una combinación farmacéutica a dosis fija de paracetamol y<br /> amitriptilina que muestran su sinergia para la reducción del dolor persistente inflamatorio y de la hipersensibilidad mecánica tras el daño neural, proporciones, seguridad y capacidad neuroprotectora.</p>
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2018000037A CU24555B1 (es) | 2018-05-07 | 2018-05-07 | Combinación a dosis fija de paracetamol:amitriptilina |
| CA3094488A CA3094488A1 (en) | 2018-05-03 | 2019-05-03 | Fixed dose composition of paracetamol: amitriptyline and method for the treatment of mixed cancer pain |
| US17/052,578 US11590091B2 (en) | 2018-05-03 | 2019-05-03 | Fixed dose composition of paracetamol: amitriptyline and method for the treatment of mixed cancer pain |
| AU2019263876A AU2019263876A1 (en) | 2018-05-03 | 2019-05-03 | Fixed dose composition of paracetamol: amitriptyline and method for the treatment of mixed cancer pain |
| CN201980029184.5A CN112055585A (zh) | 2018-05-03 | 2019-05-03 | 固定剂量的对乙酰氨基酚:阿米替林组合物和混合型癌症疼痛的治疗方法 |
| KR1020207034822A KR20210013573A (ko) | 2018-05-03 | 2019-05-03 | 파라세타몰: 아미트리프틸린의 고정 용량 조성물 및 혼합 암 통증의 치료방법 |
| EP19727583.7A EP3789020A1 (en) | 2018-05-07 | 2019-05-03 | Fixed dose composition of paracetamol: amitriptyline and method for the treatment of mixed cancer pain |
| EA202092145A EA202092145A1 (ru) | 2018-05-07 | 2019-05-03 | Композиция парацетамола: амитриптилина с фиксированной дозой и способ лечения смешанной раковой боли |
| JP2020560464A JP2021521253A (ja) | 2018-05-03 | 2019-05-03 | パラセタモール:アミトリプチリンの固定用量組成物および混合型がん性疼痛を治療するための方法 |
| BR112020019985-0A BR112020019985A2 (pt) | 2018-05-03 | 2019-05-03 | composição farmacêutica, uso de uma composição farmacêutica, e, kit |
| PCT/CU2019/050002 WO2019210889A1 (es) | 2018-05-03 | 2019-05-03 | Composición a dosis fija de paracetamol:amitriptilina y método para el tratamiento del dolor mixto por cáncer |
| CL2020002632A CL2020002632A1 (es) | 2018-05-07 | 2020-10-13 | Composición a dosis fija de paracetamol:amitriptilina y método para el tratamiento del dolor mixto por cáncer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2018000037A CU24555B1 (es) | 2018-05-07 | 2018-05-07 | Combinación a dosis fija de paracetamol:amitriptilina |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20180037A7 CU20180037A7 (es) | 2019-12-03 |
| CU24555B1 true CU24555B1 (es) | 2021-12-08 |
Family
ID=66676966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2018000037A CU24555B1 (es) | 2018-05-03 | 2018-05-07 | Combinación a dosis fija de paracetamol:amitriptilina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11590091B2 (es) |
| EP (1) | EP3789020A1 (es) |
| JP (1) | JP2021521253A (es) |
| KR (1) | KR20210013573A (es) |
| CN (1) | CN112055585A (es) |
| AU (1) | AU2019263876A1 (es) |
| BR (1) | BR112020019985A2 (es) |
| CA (1) | CA3094488A1 (es) |
| CL (1) | CL2020002632A1 (es) |
| CU (1) | CU24555B1 (es) |
| EA (1) | EA202092145A1 (es) |
| WO (1) | WO2019210889A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050176809A1 (en) * | 2004-02-05 | 2005-08-11 | Rodlen Laboratories, Inc. | Method and compositions for treatment of painful disorders |
| WO2005115360A2 (en) * | 2004-05-11 | 2005-12-08 | Becton, Dickinson And Company | Formulations of anti-pain agents and methods of using the same |
| GB0501809D0 (en) * | 2005-01-28 | 2005-03-09 | Pharmakodex Ltd | Anti-migraine formulations |
| US20130189354A1 (en) * | 2010-10-07 | 2013-07-25 | Trinity Laboratories, Inc., | Novel Pharmaceutical Compositions for Treating Chronic Pain and Pain Associated with Neuropathy |
| CA2891855A1 (en) * | 2012-12-21 | 2014-06-26 | Sykehuset Sorlandet Hf | Egfr targeted therapy of neurological disorders and pain |
-
2018
- 2018-05-07 CU CU2018000037A patent/CU24555B1/es unknown
-
2019
- 2019-05-03 JP JP2020560464A patent/JP2021521253A/ja active Pending
- 2019-05-03 EA EA202092145A patent/EA202092145A1/ru unknown
- 2019-05-03 BR BR112020019985-0A patent/BR112020019985A2/pt not_active IP Right Cessation
- 2019-05-03 CN CN201980029184.5A patent/CN112055585A/zh active Pending
- 2019-05-03 EP EP19727583.7A patent/EP3789020A1/en not_active Withdrawn
- 2019-05-03 WO PCT/CU2019/050002 patent/WO2019210889A1/es not_active Ceased
- 2019-05-03 KR KR1020207034822A patent/KR20210013573A/ko not_active Ceased
- 2019-05-03 US US17/052,578 patent/US11590091B2/en active Active
- 2019-05-03 AU AU2019263876A patent/AU2019263876A1/en not_active Abandoned
- 2019-05-03 CA CA3094488A patent/CA3094488A1/en active Pending
-
2020
- 2020-10-13 CL CL2020002632A patent/CL2020002632A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020019985A2 (pt) | 2021-01-26 |
| AU2019263876A1 (en) | 2020-11-26 |
| CU20180037A7 (es) | 2019-12-03 |
| CN112055585A (zh) | 2020-12-08 |
| WO2019210889A1 (es) | 2019-11-07 |
| US11590091B2 (en) | 2023-02-28 |
| KR20210013573A (ko) | 2021-02-04 |
| EP3789020A1 (en) | 2021-03-10 |
| EA202092145A1 (ru) | 2021-02-11 |
| JP2021521253A (ja) | 2021-08-26 |
| CL2020002632A1 (es) | 2021-02-19 |
| US20210236440A1 (en) | 2021-08-05 |
| CA3094488A1 (en) | 2019-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20025899A (es) | Compuestos útiles para inhibir a cdk7 | |
| EP3904351C0 (en) | FAK INHIBITOR AND ASSOCIATED DRUG COMBINATION | |
| NI201700101A (es) | Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina | |
| DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| MX2024000349A (es) | Compuestos y usos de los mismos. | |
| MX2018013387A (es) | Inhibidores de la arginasa y sus aplicaciones terapeuticas. | |
| MX2015010139A (es) | Composicion antiseptica oral para tratamiento de mucositis oral. | |
| AR102973A1 (es) | Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende | |
| CO2018011686A2 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant | |
| CY1122473T1 (el) | Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης | |
| MX2017003513A (es) | Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia. | |
| MX2021003033A (es) | Formulaciones de compuestos de cicloserina y aplicaciones de estas. | |
| CL2020000056A1 (es) | Nuevos derivados de xantina sustituidos. | |
| MX2017016774A (es) | Agente terapeutico para la fibrosis. | |
| MX2019001225A (es) | Compuesto aromatico heterociclico nitrogenoso, metodo de preparacion del mismo, composicion farmaceutico del mismo y aplicacion del mismo. | |
| AR101901A1 (es) | Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| EP3750537A4 (en) | PHARMACEUTICAL COMPOSITION, EXCIPIENT FOR THE COMPOSITION AND USE OF THE COMPOSITION | |
| CU24555B1 (es) | Combinación a dosis fija de paracetamol:amitriptilina | |
| CY1122979T1 (el) | Φαρμακευτικη συνθεση για τη θεραπεια της μυκητιασης | |
| CL2015003211A1 (es) | Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio. | |
| CR20170125A (es) | Composición farmacéutica sólica que comprende amlodipina y losartán | |
| PE20160245A1 (es) | Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion | |
| MX384394B (es) | Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas. | |
| MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. |